What Is the Preferred Approach to US Drug Pricing Reforms: International Reference Pricing or Value Based Pricing?
Moderators: Nirosha Mahendraratnam Lederer, PhD, MSPH, Aetion, Washington, DC, USA Ashley Jaksa, MPH, Aetion, Inc., Boston, MA, USA;
Panelists: Margaret Labban, PhD, Global Pricing Innovations, London, LON, UK; Marianne Hamilton Lopez, PhD, MPA, Duke-Margolis Center for Health Policy, Washington, DC, USA; Randy Burkholder, BA, PhRMA, Washington, DC, USA
ISSUE: The call for drug pricing reform in the United States has amplified over the past two administrations and legislation has been drafted, though not passed. IRP and VBP based on cost-effectiveness are leading the proposed reform conversations, however, it is unclear how much impact these reforms would have on actual drug pricing, patient access and affordability, value and innovation. Using an analysis comparing IRP and VBP for 23 drugs across 28 indications as a baseline understanding of the approaches, the panel will debate the results and their preferred approaches to reforms in the US.
OVERVIEW: The moderator will provide context on the current US pricing reform discussion outlining the current policy proposals, including IRP and VBP. Margaret Labban will share results from a recent analysis comparing IRP vs. VBP to set the stage for the debate. Each panelist will briefly present their perspective on US drug pricing reform. The moderator will facilitate the debate on what US drug pricing reform should look like in order to facilitate patient access and affordability without stifling innovation. The moderator will incorporate questions from the audience to enrich the debate.
Conference/Value in Health Info
Health Policy & Regulatory